Sen. Paul: GOP majority to reveal Fauci’s ties to Big Pharma
Sen. Rand Paul, R-Ky, questions Anthony Fauci, Director, National Institute of Allergy and Infectious Diseases, National Institutes of Health, while displaying a video and poster of Fauci, during the Senate Health, Education, Labor, and Pensions hearing to examine stopping the spread of monkeypox, focusing on the Federal response, in Washington, Wednesday, Sept. 14, 2022. (AP Photo/Cliff Owen)
OAN Newsroom
UPDATED 3:53 PM PT – Wednesday, September 14, 2022
Senator Rand Paul (R-Ky.) grilled National Institute of Allergy and Infectious Diseases (NIAID) Director Anthony Fauci yet again over his questionable push for mass-vaccination.
During a Senate hearing today on Wednesday, the Kentucky Senator pointed out that the government’s vaccine guidelines do not include data on previous infection which provided natural immunity. Paul stressed that the vaccine guidelines do not respect the science on natural immunity. The Senator added that he will shed light on efforts by government officials that have resulted in windfall revenues for vaccine manufacturers.
Rand Paul to Fauci:
"You refuse to answer whether anybody on the vaccine committees gets royalties from the Pharma industry… When we get in charge, we're gonna change the rules and you will have to divulge where you get your royalties from. We are going to learn about it." pic.twitter.com/4CKH9z6ibk
— Greg Price (@greg_price11) September 14, 2022
“We’ve demanded them through Freedom of Information Act and what have you said? We’re not going to tell you. But I tell you this, when we get in charge, we’re gonna change the rules and you will have to divulge where you get your royalties from (and) from what companies,” Paul said. “If anyone in the committee has a conflict of interest, we’re gonna learn about it. I promise you that.”
Senator Paul stressed that Fauci has denied the ‘very fundamental premise of immunology’ and that previous infection provides immunity in an apparent boon to vaccine-makers and the Big Pharma.